PAULA STRADINA KLINISKA UNIVERSITATES SLIMNICA

Their core work

Pauls Stradiņš Clinical University Hospital is Latvia's largest tertiary care hospital, providing real-world clinical settings and patient cohorts for multinational medical research. Their H2020 contribution spans two distinct domains: acute cardiac emergency care — specifically cardiogenic shock and ECMO therapy evaluated through a randomized controlled trial — and technology-enabled intensive care, where they validated cyber-physical systems and AI-powered telemedicine during the COVID-19 crisis. They act as a clinical validation partner: bringing patients, physicians, and bedside expertise into large European consortia that need a Baltic trial site. For researchers and technology developers, they are a gateway to an underrepresented EU patient population in a hospital environment open to testing advanced medical technologies.

What they specialise in

How they've shifted over time

Their earliest H2020 engagement (EURO SHOCK, 2018) was purely clinical — a randomised trial investigating whether an aggressive interventional strategy improves survival in cardiogenic shock, including ECMO as a salvage therapy. By 2021, their second project (ICU4Covid) shows a clear pivot: the keywords shift from bedside cardiology to cyber-physical systems, robotics, AI-driven telemedicine, and continuous remote monitoring of ICU patients. This is a meaningful transition — from participating as a clinical trial site to becoming a validation hospital for digital health and medical robotics technologies.

They are moving toward becoming a hospital that actively validates digital health and medical robotics technologies inside live ICU environments — making them increasingly relevant to MedTech and AI health companies seeking clinical validation partners in the Baltics.

How they like to work

They have participated exclusively as consortium partners — never as coordinator — which is typical for a clinical hospital whose primary value is patient access and bedside expertise rather than project management capacity. Despite only two projects, they engaged with 44 unique partners across 15 countries, which means they joined large, multi-partner international consortia where their clinical contribution was one specialised piece of a broader research effort. Working with them means gaining a credible Baltic clinical site that is comfortable operating inside complex multi-national research structures.

With 44 unique consortium partners across 15 countries from just two projects, Stradiņš Hospital has plugged into sizeable pan-European research networks, primarily in the health domain. Their reach extends well beyond the Baltic region, though they have no documented coordinator relationships that would indicate a hub role.

What sets them apart

As the largest university hospital in Latvia, they offer access to a patient population that remains underrepresented in European clinical research, which is directly valuable for trials requiring geographic diversity across EU member states. Their dual track record — traditional randomised cardiology trials on one hand, and cyber-physical ICU systems on the other — signals a hospital willing to host both established clinical research and emerging medical technology validation. For consortium builders needing a Baltic critical care partner with documented openness to AI and robotics trials, they are a rare and specific asset in the region.

Highlights from their portfolio

• ICU4Covid
  Largest EC award of the two projects (EUR 95,984) and marks a decisive pivot toward AI, robotics, and cyber-physical systems in intensive care — signals the hospital's readiness to validate digital health technology in a live clinical environment.
• EURO SHOCK
  A high-stakes multinational randomised controlled trial on cardiogenic shock and ECMO — one of the most difficult acute cardiac conditions to study — demonstrating the hospital's capacity to enroll complex critical care patients in rigorous trial protocols.